UNSPSC 51432306: Olmesartan

This classification denotes an angiotensin ii receptor antagonist with the molecular formula C29H30N6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6M97XTV3HD, chemically known as 1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2-(1h-tetrazol-5-yl) (1,1-biphenyl)-4-yl)methyl)- but generally known as olmesartan, which bears US NIH Compound Identifier 158781. European Medicines Agency schedules Olmesartan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20707.

UNSPSC 51432306 Olmesartan is a Commodity code covering a single pharmaceutical product — the antihypertensive medication olmesartan — but recent state and local procurement activity under this code shows minimal direct use. The sole recent opportunity in the dataset is the City of Tampa's April 2026 sealed-bid solicitation for Advanced Life Support Medications (Bid No. 26-P-00188) issued for Tampa Fire Rescue, which sought four specific emergency medications (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem) with no olmesartan component. The mismatch between the code's nominal scope and the actual work being solicited suggests that olmesartan procurement either occurs at lower volume, is bundled into broader pharmaceutical agreements, or may be tagged inconsistently across jurisdictions. Fire rescue and emergency medical services agencies are among the state and local buyers active in this pharmaceutical class, but the single opportunity does not establish a pattern of olmesartan-specific demand.

The City of Tampa represents the only recent issuing body in the available record. The April 2026 solicitation, issued through OpenGov eProcurement, targeted a $40,000 estimated contract value with firm pricing inclusive of shipping and applicable taxes, a one-year base term with two optional one-year renewals plus unilateral extension authority for up to three 30-day periods, and a Small Local Business Enterprise sheltered-market set-aside with a 5 percent bid discount capped at $10,000. Vendors were required to deliver within ten calendar days and maintain nine-month minimum expiration dating, with replacement liability for expired stock. The response deadline of April 8, 2026 has passed; given the lack of additional olmesartan opportunities in the recent dataset, this code shows limited current activity worth pursuing at the state and local level without further research into other jurisdictions or bundled pharmaceutical frameworks.